Cannabidiol and Beta-Caryophyllene: Chronic inflammatory pain
Abstract While chronic pain is challenging to manage, it always co-exists with depression. Currently, chronic pain and depression are usually treated separately with distinct approaches, yet effectiveness remains elusive. Consequently, the development of integrated therapeutic strategies for pain while addressing depression is a high public health priority and unmet need that affects millions of people. This study aims to determine if the combination of the two phytocannabinoids Beta-Caryophyllene (BCP) and cannabidiol (CBD) is effective for chronic pain while simultaneously showing
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join — it's freeAlready a member? Log in
